About: SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway
Creator	Chen, Yang Jiang, Yong Hu, Jian-Zhong Li, Zhuo-Ran Liu, Quan-Zhong
Source	PMC
abstract	Basal cell carcinoma (BCC) is the most common type of human skin cancer, which is driven by the aberrant activation of Hedgehog signaling. Previous evidence indicated that sex determining region Y-box 2 (SOX2) is associated with the tumor metastasis. However, the expression and role of SOX2 in BCC remain unknown. Therefore, the aim of the current study was to analyze the possible mechanism of SOX2 in the progression of BCC. The levels of SOX2 in BCC cells were detected by reverse transcription-quantitative polymerase chain reaction. Transwell assays were also used to determine the migration and invasion of BCC cells. Immunoblotting and immunofluorescence were used for analyzing the role of SOX2 knockdown in the serine-arginine protein kinase 1 (SRPK1)-mediated phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway in BCC cells. The results demonstrated that SOX2 is overexpressed in BCC tissues and cells. In addition, SOX2 knockdown inhibited the migration and invasion of BCC cells, and the epithelial-mesenchymal transition (EMT) progress of BCC cells. It was also observed that SOX2 knockdown decreased SRPK1 expression, which further led to the downregulation of PI3K and AKT expression levels in BCC cells. Furthermore, SRPK1 transfection or PI3K/AKT pathway activation abolished the inhibitory effects of SOX2 knockdown on the migration, invasion and EMT progress of BCC cells. In conclusion, these results indicated that SOX2 may potentially serve as a target for BCC therapy by targeting the SRPK1-mediated PI3K/AKT signaling pathway.
has issue date	2018-12-07(xsd:dateTime)
bibo:doi	10.3892/ol.2018.9810
bibo:pmid	30675221
has license	cc-by-nc-nd
sha1sum (hex)	d6da8802866acb6cd35ee1c4a0ec6c64d06b8345
schema:url	https://doi.org/10.3892/ol.2018.9810
resource representing a document's title	SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway
has PubMed Central identifier	PMC6341784
has PubMed identifier	30675221
schema:publication	Oncol Lett
resource representing a document's body	covid:d6da8802866acb6cd35ee1c4a0ec6c64d06b8345#body_text
is schema:about of	named entity 'IMMUNOBLOTTING' named entity 'PREVIOUS' named entity 'AKT' named entity 'BOX' named entity 'STUDY' named entity 'PROGRESSION' named entity 'INVASION' named entity 'HUMAN SKIN' named entity 'DOWNREGULATION' named entity 'QUANTITATIVE POLYMERASE CHAIN REACTION' named entity 'POSSIBLE' named entity 'PHOSPHOINOSITIDE 3-KINASE' named entity 'THESE' named entity 'CELLS' named entity 'ANALYZING' named entity 'OBSERVED' named entity 'ASSOCIATED WITH' named entity 'PATHWAY' named entity 'PROTEIN KINASE' named entity 'SERVE' named entity 'RESULTS' named entity 'migration' named entity 'SOX2' named entity 'signaling pathway' named entity 'remain' named entity 'knockdown' named entity 'cells' named entity 'PI3K' named entity 'SOX2' named entity 'AKT' named entity 'AKT' named entity 'SOX2' named entity 'immunofluorescence' named entity 'PI3K' named entity 'phosphoinositide 3-kinase' named entity 'basal cell carcinoma' named entity 'migration' named entity 'signaling pathway' covid:arg/d6da8802866acb6cd35ee1c4a0ec6c64d06b8345 named entity 'EPITHELIAL-MESENCHYMAL TRANSITION' named entity 'USED' named entity 'PI3K' named entity 'CARCINOMA CELLS' named entity 'SIGNALING PATHWAY' named entity 'ARGININE' named entity 'WORDS' named entity 'KINASE' named entity 'ARGININE' named entity 'PROGRESS' named entity 'EMT' named entity 'SKIN CANCER' named entity 'SEX DETERMINING REGION Y' named entity 'PROTEIN KINASE' named entity 'SOX2' named entity 'KEY' named entity 'MEDIATED' named entity 'INVASION' named entity 'MIGRATION' named entity 'SRPK1' named entity 'BOX' named entity 'SERINE' named entity 'TARGETING' named entity 'REVERSE TRANSCRIPTION' named entity 'AIM' named entity 'SIGNALING PATHWAY' named entity 'ABERRANT' named entity 'SOX2' named entity 'LEVELS' named entity 'MECHANISM' named entity 'CURRENT' named entity 'EVIDENCE' named entity 'ADDITION' named entity 'IMMUNOFLUORESCENCE' named entity 'EFFECTS' named entity 'TARGETING' named entity 'LED' named entity 'COMMON'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software